Biohit Oyj

Helsinki Stock Exchange BIOBV.HE

Biohit Oyj Gross Profit for the year ending December 31, 2023: USD 9.14 M

Biohit Oyj Gross Profit is USD 9.14 M for the year ending December 31, 2023, a 20.18% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Biohit Oyj Gross Profit for the year ending December 31, 2022 was USD 7.61 M, a 13.01% change year over year.
  • Biohit Oyj Gross Profit for the year ending December 31, 2021 was USD 6.73 M, a 39.24% change year over year.
  • Biohit Oyj Gross Profit for the year ending December 31, 2020 was USD 4.83 M, a -35.38% change year over year.
  • Biohit Oyj Gross Profit for the year ending December 31, 2019 was USD 7.48 M, a 1.50% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Loading...
Helsinki Stock Exchange: BIOBV.HE

Biohit Oyj

CEO Prof. Osmo Antero Suovaniemi M.D., Ph.D.
IPO Date Jan. 3, 2000
Location Finland
Headquarters Laippatie 1
Employees 47
Sector Health Care
Industries
Description

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.

Similar companies

SSH1V.HE

SSH Communications Security Oyj

USD 1.04

-0.38%

TEM1V.HE

Tecnotree Oyj

USD 2.63

-1.33%

BITTI.HE

Bittium Oyj

USD 6.70

1.23%

StockViz Staff

January 15, 2025

Any question? Send us an email